A new type of blood test may help physicians identify which patients with and without evidence of coronary blockages are at risk for heart attacks and strokes. Even individuals with normal levels of low-density lipoprotein (LDL), known as the so-called “bad” cholesterol, but still at risk, seem to be identified.

By Mayo Clinic News Network • March 14, 2017

In February 2017, Mayo Medical Laboratories announced nine brand new tests along with numerous reference-value changes, obsolete tests, and algorithm changes.

By Alyssa Frank • March 9, 2017

Mayo Clinic has completed validation of its existing Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum test for the new biosimilar drug Inflectra. Clients[...]

By Mayo Clinic Laboratories • March 7, 2017

In cases of sudden or unexpected death, autopsy evaluation can include a biochemical analysis to identify deaths caused by fatty acid oxidation disorders.

By Communiqué Archive • November 16, 2016

The new Gastrointestinal Pathogen Panel, PCR, Feces test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients.

By Brent Westra • March 10, 2016